Key result
Breast cancer radiotherapy linked to ~27% lower risk of cardiovascular events at 10 years.
Why the study?
The study aimed to examine the impact of radiotherapy on the cardiovascular health of women diagnosed with breast cancer in the Waikato region of New Zealand.
Does radiotherapy affect cardiovascular morbidity and mortality in women with stage 0-III breast cancer?
Cohort (n=3,528)
Does radiotherapy affect cardiovascular morbidity and mortality in women with stage 0-III breast cancer?
Effect estimate: HR 0.73 (95% CI 0.59-0.92)
Absolute Event Rate: 11.7% vs 19.4%
Current breast cancer radiotherapy regimens do not appear to increase the 10-year risk of cardiovascular events, suggesting that traditional cardiovascular risk factors remain the primary drivers of disease in this population.
May support cardiovascular safety of modern radiotherapy in early breast cancer; leaves open residual confounding in this observational association.
INTRODUCTION: This study aims to examine the impact of radiotherapy on the cardiovascular health of women diagnosed with breast cancer in the Waikato region in New Zealand. METHODS: Women diagnosed with stage 0-III breast cancer and recorded in the Waikato Breast Cancer Registry were divided into two groups: a radiotherapy group and a no-radiotherapy group. Baseline characteristics and treatments were compared in the two groups. Kaplan-Meier survival analysis was performed to compare cardiovascular morbidity and mortality. Cox Proportional Hazard regression analysis was used to estimate the hazard ratio of radiotherapy on the risk of cardiovascular morbidity and mortality while adjusting for other factors. RESULTS: A total of 3528 women were included in this study, with 2303 in the radiotherapy group and 1225 in the no-radiotherapy group. At 10-year follow-up, 11.7% of women in the radiotherapy group and 19.4% in the no-radiotherapy group experienced cardiovascular events. Only 2.3% of patients who received radiotherapy died of cardiovascular disease by 10 years compared to 7.0% in the no-radiotherapy group. After adjusting for clinically significant factors, there was unexplained reduced risk of developing cardiovascular disease in the radiotherapy group compared to the no-radiotherapy group (HR 0.73, 95% CI: 0.59-0.92). No significant difference was found in cardiovascular mortality between the two groups. CONCLUSIONS: Radiotherapy appears less likely to be offered to patients at higher risk of cardiovascular disease. No evidence of increased risk of a cardiovascular event was found in the group of women with breast cancer treated with radiotherapy and current regimens appear safe. Traditional cardiovascular risk factors remain the main culprits in this setting. Clinicians should work with patients in managing these risk factors for optimal results.
No takes yet. Share an insight, caveat, or question.
Lawrenson et al. (2018) conducted a cohort in Stage 0-III breast cancer (n=3,528). Radiotherapy vs. No radiotherapy was evaluated on Cardiovascular morbidity (developing cardiovascular disease) (HR 0.73, 95% CI 0.59-0.92). Radiotherapy in women with stage 0-III breast cancer was associated with a reduced risk of cardiovascular events compared to no radiotherapy (HR 0.73; 95% CI 0.59-0.92) at 10 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: